Cargando…

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

In many recurrent and/or metastatic cancers, the advent of immunotherapy opens up new scenarios of treatment response, with new phenomena, such as pseudoprogression and hyperprogression. Because of this, different immune-related response criteria have been developed, and new therapeutic strategies a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alberti, Andrea, Lorini, Luigi, Ravanelli, Marco, Perri, Francesco, Vinches, Marie, Rondi, Paolo, Romani, Chiara, Bossi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228441/ https://www.ncbi.nlm.nih.gov/pubmed/35746493 http://dx.doi.org/10.3390/vaccines10060885

Ejemplares similares

Confounding factors in the assessment of oral mucositis in head and neck cancer
por: Lorini, Luigi, et al.
Publicado: (2022)

Advanced Cutaneous Squamous Cell Carcinoma Management in Immunotherapy Era: Achievements and New Challenges
por: Lorini, Luigi, et al.
Publicado: (2023)

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
por: Klinghammer, Konrad, et al.
Publicado: (2022)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies
por: Ionna, Franco, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer
por: Plavc, Gaber, et al.
Publicado: (2020)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
por: Colombo, Elena, et al.
Publicado: (2023)

The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials
por: Fortpied, Catherine, et al.
Publicado: (2019)

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
por: Alberti, Andrea, et al.
Publicado: (2022)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
por: Bossi, Paolo, et al.
Publicado: (2021)

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
por: Flanagan, Kevin C., et al.
Publicado: (2023)

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?
por: Longo, Francesco, et al.
Publicado: (2020)

Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?
por: Bossi, Paolo, et al.
Publicado: (2021)

Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
por: Bossi, Paolo, et al.
Publicado: (2016)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Ghosh, Soma, et al.
Publicado: (2022)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
por: Lorch, Jochen H
Publicado: (2009)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Clinical and Histological Prognostic Factors of Recurrence and Malignant Transformation in a Large Series of Oral Potentially Malignant Disorders
por: Lorini, Luigi, et al.
Publicado: (2022)

Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Peng, Ying-Peng, et al.
Publicado: (2021)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021)

The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma
por: Salvestrini, Viola, et al.
Publicado: (2022)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat
por: Perri, Francesco, et al.
Publicado: (2020)

Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer
por: Abbas, Waseem, et al.
Publicado: (2021)

Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: González‐García, Ignacio, et al.
Publicado: (2021)

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
por: Clancy, Kate, et al.
Publicado: (2021)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer?
por: Bossi, Paolo
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3v9eht69d6l3j6h563odi44n3h